LENZ Therapeutics’ Post

Bespoke posts on X: These are the 38 stocks in the S&P 1500 that are up 100%+ on the year with six trading days left. Who had Abercrombie & Fitch $ANF on their list of top performers at the start of the year? It's currently up more than any other stock in the index with a YTD gain of nearly 300%. Link: https://lnkd.in/g5iqGBmd My take: If you think ANF had impressive gains this year, come into my biotech universe and check out gains in Soleno Therapeutics (SLNE), Gyre Therapeutics (GYRE), EyePoint Pharmaceuticals (EYPT), Viking Therapeutics (VKTX) and a bunch more biotechs that doubled and quadrupled from their bottom and were great to trade this year. Anyway, have fun looking at the list below, good to know in case one of your relatives annoys you this holiday season about how much money they made in the stock market. 😁

Does NeuBase Therapeutics (USA Stocks:NBSE) have sound basic indicators based on the latest surge?: We offer an investment recommendation to supplement the latest expert consensus on NeuBase Therapeutics. Our advanced recommendation engine uses a multidimensional algorithm to assess the company's growth potential, considering all available technical and fundamental data. The firm's dividend policy can hint at the stock's current value. NeuBase Therapeutics is not anticipated to issue dividends this year as it aims to conserve or reinvest any distributable funds. However, investing in non-dividend stocks can still yield capital appreciation. Investors in such stocks depend on the stock's price increase over time for returns. If the company performs well and its stock price escalates, investors can sell their shares at a higher price for a profit. Important Takeaways NeuBase Therapeutics (NASDAQ: NBSE) has recently seen a bullish surge, but a closer look at its fundamentals raises some concerns. The company has a significant operating loss of $33.3M, and a net income loss of $33.8M. This is reflected in a negative return on equity of -0.93. However, the company has a solid cash position with cash and short-term investments totaling $23.2M. This could potentially provide a buffer against its operating losses, but the company's financial health will largely depend on its ability to generate positive income in the future. Therefore, potential investors should proceed with caution.Continue To Read... https://lnkd.in/gR-sVcBz

Beware of sudden volatility, trading models used can be put to the test especially on the American market, where there are practically no suspensions. These violent behaviors are typical of biopharmaceutical and undercapitalized stocks. Candel Therapeutics Inc - NASDAQ - IB - Pro Real Time Trading #finance #HFG #trading #economy #quant #money

$NLTX - Next financial report expected on 13th of May 2024.: About 16.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.44. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Neoleukin Therapeutics recorded a loss per share of 12.28. The entity had not issued any dividends in recent years. The firm had 1:4 split on the 19th of December 2023. #stocks #stocktwits #thematic_portfolio

Get in on the Ground Floor: ReNAD Series Seed Preferred Stock 1 in 1000. Those are the odds of surviving two years after a fentanyl overdose. Allow me to introduce my personal story and a unique, time-limited investment opportunity in ReNAD Biologics' Series Seed Preferred Stock. In full transparency, we are offering this round at a temporarily discounted valuation due to an unexpected investor changing commitments late in the process. While an impartial third-party analysis suggests a valuation of $8.2 million, we are offering this round at $2 million to account for the unexpected headwinds. This is not an indication of the company's immense potential and progress. It is a chance to buy into that upside at an attractive valuation. The sheer magnitude of the opportunity remains unchanged.

Xenetic Biosciences Stock Plummets 30% In Recent Decline (VIANEWS) – Xenetic Biosciences (XBIO) shares have fallen by 30.52% over 21 sessions, from EUR4.39 to EUR3.05 as of 17:23 EST Thursday afternoon. This drop follows an earlier downward trend; although overall NASDAQ performance rose 0.08% to EUR13,650.41 during that same timeframe; XBIO’s drop represents an unexpected setback from recent gains; current share prices stand […] https://lnkd.in/gV-R2maE - Read more.

Should you shadow Atara Biotherapeutics (USA Stocks:ATRA) insiders in March?: They say timing is everything in the stock market, and for shareholders of Atara Biotherapeutics, a biotechnology firm in the healthcare sector, this adage rings particularly true. With a 52-week high of $4.68, the stock is currently trading at a mere $0.83, a significant drop that may be causing investors to question their holdings. The company's estimated earnings per share (EPS) for the next year is projected to be a loss of $1.48, and with a short ratio of 1.9, it's clear that some investors are betting on the stock's further decline. However, with an analyst overall consensus rating of 'Hold' and a possible upside price of $13.08, the question remains: Is now the optimal moment to liquidate Atara Biotherapeutics stock? Currently, Atara Biotherapeutics' Average Equity is projected to see significant growth, based on reports from the past few years. The company's Enterprise Value for the current year is expected to rise to approximately $360.9 million. However, the Net Income Per Employee is predicted to decrease to -$663.8K. This article aims to predict the future value of Atara Biotherapeutics using technical analysis. So, what should investors of Atara Biotherapeutics anticipate in March?Continue To Read... https://lnkd.in/eAw8tfcy

How does a Zacks #1 (Strong Buy) or Zacks #2 (Buy) ranking correlate with actual performance?   Shares of MakeMyTrip Limited (MMYT), a Zacks Rank #1, gained +15.81% (versus the S&P 500’s -3.44% decline). Shares of Corcept Therapeutics (CORT), a Zacks Rank #2, gained +10.2% (versus the S&P 500’s -3.66% fall). These gains are for the period since these stocks' rankings were upgraded in early August.   Zacks Rank is our short-term rating system that has earnings estimates revisions at its core. Empirical research shows a strong correlation between trends in earnings estimates revisions and near-term stock price movements. Learn more about Zacks research performance and see more of our latest performance numbers with our free weekly performance update. https://lnkd.in/gETFgdSS #EconomicAnalysis #ZacksRank #FinancialAnalysis #ExpertInsights

Buy & Sell Signals When Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock ($CYCCP) Moves Investors should Listen: Stock Traders Daily has produced this trading report using a proprietary method.  This methodology [...] Look at the Charts

📉 VKTX takes a tumble, dropping 10.9% 📉 What caused the dip? Stay informed about market movers! #VKTX #StockMarket #Investing #Finance ## Viking Therapeutics Inc (VKTX) Sees 10.9% Drop in Shares Despite Lack of News Viking Therapeutics Inc (VKTX) shares are trading lower by 10.9% to $63.95 Monday afternoon, despite a lack of company-specific news for the session. The stock experienced marked strength in February after the company announced the Phase 2 VENTURE trial successfully achieved its primary endpoint and all secondary endpoints. However, VKTX has also seen volatility in recent sessions after the company announced its public offering of 6.471 million common shares at $85 per share. ### Is VKTX A Good Stock To Buy? Investors evaluating VKTX may consider various factors beyond just price movements. Viking Therapeutics does not pay a dividend, but it has other avenues to return value to shareholders, such as through buyback programs. Buyback programs are variable and can impact share prices by providing a support level for demand. Monitoring news for announcements on buyback programs can give insight into the company's strategic decisions. This article is not intended as investment advice. Investors should conduct thorough research and analysis before making any investment decisions in VKTX or any other stock. Read the full article at: https://lnkd.in/gCSHB7Hd